Our results showed that GSCAR-targeting ASOs alone or in combination with TMZ markedly inhibited glioma tumor cell growth both in vitro and in vivo, suggesting that GSCAR is a promising therapeutic target for glioma patients in the future. This evidence concerns the gene GSCAR and central nervous system cancer.